Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A practical approach to screening psoriasis patients for therapy with biologic agents.

Literature DB >> 21203363

A practical approach to screening psoriasis patients for therapy with biologic agents.

Abstract

The use of biologic agents for the treatment of psoriasis and psoriatic arthritis is increasingly growing among dermatologists. Proper screening is crucial to select patients who are appropriate candidates for these drugs. This article will outline a practical approach to evaluating patients, focusing on key aspects of the medical history, physical examination, and laboratory testing.

Entities: Disease Species

Year: 2008 PMID： 21203363 PMCID： PMC3014311

Source DB: PubMed Journal: J Clin Aesthet Dermatol ISSN： 1941-2789

36 in total

1. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

Authors: E G Favalli; L Sinigaglia; M Varenna; C Arnoldi
Journal: Lupus Date: 2002 Impact factor: 2.911

2. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.

Authors: A W A M van Rijthoven; J W J Bijlsma; M Canninga-van Dijk; R H W M Derksen; J A G van Roon
Journal: Rheumatology (Oxford) Date: 2006-07-13 Impact factor: 7.580

3. Adalimumab-associated multiple sclerosis.

Authors: Lamiae Bensouda-Grimaldi; Denis Mulleman; Jean-Pierre Valat; Elisabeth Autret-Leca
Journal: J Rheumatol Date: 2007-01 Impact factor: 4.666

4. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.

Authors: Pilar Martinez Montiel; Jose Antonio Solis; Juan Antonio Chirinos; Begoń a Casis; Fernando Sánchez; Sarbelio Rodríguez
Journal: Liver Int Date: 2008-05 Impact factor: 5.828

5. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors: J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal: Ann Rheum Dis Date: 2005-04-20 Impact factor: 19.103

1. Anti-tumor necrosis factor drug responses and skin-blood DNA methylation age: Relationships in moderate-to-severe psoriasis.

Authors: Jamaji C Nwanaji-Enwerem; Ugoji Nwanaji-Enwerem; Andrea A Baccarelli; Ramone F Williams; Elena Colicino
Journal: Exp Dermatol Date: 2020-10-17 Impact factor: 3.960

1 in total

A practical approach to screening psoriasis patients for therapy with biologic agents.

1. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

2. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.

3. Adalimumab-associated multiple sclerosis.

4. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.

5. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

6. Etanercept and demyelinating disease in a patient with psoriasis.

7. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.

8. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

9. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

10. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

1. Anti-tumor necrosis factor drug responses and skin-blood DNA methylation age: Relationships in moderate-to-severe psoriasis.